Cantor Fitzgerald Initiates Coverage on Prenetics with “Overweight” Rating

HONG KONG, Jan 26, 2023 – (ACN Newswire via SEAPRWire.com) – It is reported that Cantor Fitzgerald initiated coverage on Prenetics Global (PRE.US) with “Overweight” rating and target price at USD7.00. Cantor Fitzgerald holds a favorable view of the consumer and clinical testing markets, with Prenetics’ focus on diagnostic and preventive testing coupled with personalized […]

Prenetics Acquires ACT Genomics; First M&A Deal since IPO, Set to Expand Footprint in Cancer Genomics

HONG KONG, Dec 16, 2022 – (ACN Newswire via SEAPRWire.com) – Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, is acquiring a majority stake of ACT, an Asia based genomics company specializing in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand and the […]

Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index

LONDON AND HONG KONG, Nov 30, 2022 – (ACN Newswire via SEAPRWire.com) – Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced that its board of directors has authorized a share repurchase program, and that it has been included as a constituent stock in the […]

Citi Initiates Coverage on Prenetics Global with “Buy” Rating, Target Price at USD8.10

HONG KONG, Jul 13, 2022 – (ACN Newswire via SEAPRWire.com) – It is reported that Citi initiated coverage on Prenetics Global (PRE.US) with “Buy” rating. Target price is at USD8.10, apply 3x P/S 2023E, at parity with the industry average. As Covid-19 variants have continued to spread, Citi believes Covid-19 testing will remain a solid […]